Literature DB >> 9029072

Deletion and conversion in spinal muscular atrophy patients: is there a relationship to severity?

C J DiDonato1, S E Ingraham, J R Mendell, T W Prior, S Lenard, R T Moxley, J Florence, A H Burghes.   

Abstract

The spinal muscular atrophy-determining gene, survival motor neuron (SMN), is present in two copies, telSMN and cenSMN, which can be distinguished by base-pair changes in exons 7 and 8. The telSMN gene is often absent in spinal muscular atrophy patients, which could be due to deletion or sequence conversion (telSMN conversion to cenSMN giving rise to two cenSMN genes). To test for conversion events in spinal muscular atrophy, we amplified a 1-kb fragment that spanned exons 7 and 8 of SMN from 5 patients who retained telSMN exon 8 but lacked exon 7. In all patients, sequence analysis demonstrated that cenSMN exon 7 was adjacent to telSMN exon 8, indicating conversion. All 5 patients with this mutation had type II or III spinal muscular atrophy, strongly supporting an association with chronic spinal muscular atrophy. We also identified 3 families in which 2 siblings had no detectable telSMN but presented with markedly different phenotypes. We suggest that sequence conversion is a common event in spinal muscular atrophy and is associated with the milder form of the disease. The severity, however, can be modified in either a positive or negative direction by other factors that influence splicing or expression of the sequence converted SMN gene.

Entities:  

Mesh:

Year:  1997        PMID: 9029072     DOI: 10.1002/ana.410410214

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

1.  Molecular study of spinal muscular atrophy patients with hybrid genes in Bulgaria.

Authors:  I Kremensky; S Jankova; E Bochukova; M Uzunova; I Litvinenko; A Jordanova
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

Review 2.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

3.  De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling.

Authors:  B Wirth; T Schmidt; E Hahnen; S Rudnik-Schöneborn; M Krawczak; B Müller-Myhsok; J Schönling; K Zerres
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

Review 4.  Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.

Authors:  P C Wong; H Cai; D R Borchelt; D L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Maternal mosaicism for a second mutational event in a type I spinal muscular atrophy family.

Authors:  L Campbell; R J Daniels; V Dubowitz; K E Davies
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 6.  When is a deletion not a deletion? When it is converted.

Authors:  A H Burghes
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

Review 7.  Targeting RNA-splicing for SMA treatment.

Authors:  Jianhua Zhou; Xuexiu Zheng; Haihong Shen
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

8.  Spinal muscular atrophy genetic testing experience at an academic medical center.

Authors:  Shuji Ogino; Debra G B Leonard; Hanna Rennert; Robert B Wilson
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

Review 9.  Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.

Authors:  Alyssa N Calder; Elliot J Androphy; Kevin J Hodgetts
Journal:  J Med Chem       Date:  2016-08-16       Impact factor: 7.446

10.  Detection of SMN1 to SMN2 gene conversion events and partial SMN1 gene deletions using array digital PCR.

Authors:  Deborah L Stabley; Jennifer Holbrook; Mena Scavina; Thomas O Crawford; Kathryn J Swoboda; Katherine M Robbins; Matthew E R Butchbach
Journal:  Neurogenetics       Date:  2021-01-07       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.